Sunday 18 October 2026
Export SCTX’s income statement to Excel — free account
Scribe Therapeutics Inc.
SCTX
Insiders bought in the last twelve months.
20.08
0.64
−3.09%
Follow SCTX
| Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|
P/S ratio |
0.00 | — | 0.00 |
P/FCF ratio |
0.00 | — | 0.00 |
P/Operating CF |
0.00 | — | 0.00 |
P/B ratio |
0.00 | — | 0.00 |
Price to Tangible BV |
0.00 | — | 0.00 |
EV/Sales |
0.00 | — | 0.00 |
EV/EBITDA |
0.00 | — | 0.00 |
EV/Operating CF |
0.00 | — | 0.00 |
EV/FCF |
0.00 | — | 0.00 |
Quick Ratio |
— | 0.94 | 0.56 |
Current Ratio |
— | 0.97 | 0.57 |
Net Debt/EBITDA |
0.00 | 0.00 | 4.58 |
Debt/Assets |
— | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 |
Operating CF/Net income |
0.00 | — | 0.00 |
Interest Coverage |
(19.44) | — | (34.04) |
Research and Development Expense of Revenue |
283.46% | — | 460.01% |
Selling, General and Administrative Expense of Revenue |
53.92% | — | 129.82% |
Intangible Assets out of Total Assets |
— | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | — | 0.00% |
Graham Net Nets |
(1.22) | — | (1.22) |
Graham Number |
0.00 | — | 0.00 |
Free Cash Flow Yield |
0.00% | — | 0.00% |
Revenue per Share |
2.02 | — | 0.77 |
Operating CF per Share |
0.00 | — | 0.00 |
Capex per Share |
0.00 | — | 0.00 |
Free Cash Flow per Share |
0.00 | — | 0.00 |
Cash per Share |
0.00 | 0.00 | 17.37 |
Shareholders Equity per Share |
0.00 | 0.00 | (17.97) |
Interest Debt per Share |
0.00 | — | 0.00 |
Book value per Share |
0.00 | 0.00 | (17.97) |
EV/EBIT |
0.00 | — | 0.00 |
Capex to Sales |
0.00 | — | 0.00 |
Price to Operating Income |
0.00 | — | 0.00 |
| Other line items | |||
Working Capital |
— | (2.12) | (33.59) |
Net Current Asset Value |
— | (34.35) | (57.31) |
Columns are period end dates · fundamentals updated 29 Sep 2026